To facilitate high-quality patient care and to include new and emerging evidence, the American College of Rheumatology (ACR) has developed and updated the guidelines for the management of rheumatoid arthritis (RA).
Our featured guest on this episode is Stanley Cohen, MD, who provides a glimpse into the scope and new updates to the ACR guidelines, which are currently in the draft stage.
Stanley Cohen, MD, completed a degree in biology from the University of Virginia and received his doctor of medicine with honors from the University of Alabama School of Medicine in Birmingham. He completed an internship and residency in internal medicine at Parkland Memorial Hospital, Dallas, Texas, and a fellowship in rheumatology at UT Southwestern/St Paul University Hospital in Dallas.
For the last 36 years, Dr Cohen has been involved in clinical trials in RA. He has been a principal investigator, played pivotal roles in protocol development and data analysis, and an author on multiple peer-reviewed articles in this field. Dr Cohen’s research group has participated in the development of nearly all the biologic therapies and targeted synthetic disease-modifying antirheumatic drugs developed for RA in the last 22 years.
In addition to these research interests, Dr Cohen has been involved in training medical students, residents, and rheumatology fellows through his association with UT Southwestern as a clinical professor of internal medicine and as co-director of the rheumatology program at St Paul Medical Center in Dallas, and now, as co-director of the rheumatology program at Presbyterian Hospital in Dallas. He is a past president of ACR and was honored in 2016 with the designation of Master.
Dr Cohen is also part of a large single specialty group in the private practice of rheumatology, which has 21 rheumatologists and more than 3000 patients with RA.